Advertisement

A novel two nucleotide deletion in the apolipoprotein A-I gene, apoA-I Shinbashi, associated with high density lipoprotein deficiency, corneal opacities, planar xanthomas, and premature coronary artery disease

      Abstract

      Familial HDL deficiency (FHD) is a rare autosomal dominant lipoprotein disorder. We describe a novel genetic variant of the apolipoprotein A-I (apoA-I) gene resulting in FHD. The proband is a 51-year-old woman who was hospitalized due to severe heart failure. Her plasma HDL-cholesterol (C) and apoA-I concentrations were 0.08 mmol/l and 1 mg/dl, respectively. She exhibited corneal opacities and planar xanthomas on eyelids and elbows. Coronary angiography demonstrated extensive obstructions in two major vessels. Genomic DNA sequencing of the patient’s apoA-I gene revealed a homozygosity for a GC deletion between 5 GC repeats in exon 4, creating a frameshift and a stop codon at residue 178. We designated this mutation as apoA-I Shinbashi. The proband’s father, son, and daughter were found to be heterozygous for this mutation and their HDL-C and apoA-I levels were about half of normal levels, demonstrating a gene dosage effect. The father underwent coronary bypass surgery at age of 70 years. Lecithin–cholesterol acyltransferase (LCAT) activity was decreased by 63% in the homozygote and 31% in heterozygotes, respectively. This new case of apoA-I deficiency, apoA-I Shinbashi, is the first case involving a single gene defect of the apoA-I gene to develop all the characteristics for apoA-I deficiency, including premature coronary heart disease.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Gordon D.J.
        • Rifkind B.M.
        High-density lipoprotein—the clinical implications of recent studies.
        N Engl. J. Med. 1989; 321: 1311-1316
        • Glomset J.A.
        The plasma lecithins:cholesterol acyltransferase reaction.
        J. Lipid Res. 1968; 9: 155-167
        • Stampfer M.J.
        • Sacks F.M.
        • Salvini S.
        • Willett W.C.
        • Hennekens C.H.
        A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction.
        N Engl. J. Med. 1991; 325: 373-381
        • Coleman M.P.
        • Key T.J.A.
        • Wang D.Y.
        A prospective study of obesity, lipids, apolipoproteins and ischemic heart disease in women.
        Atherosclerosis. 1992; 92: 177-185
        • Oram J.F.
        • Lawn R.M.
        ABCA1. The gatekeeper for eliminating excess tissue cholesterol.
        J. Lipid Res. 2001; 42: 1173-1179
        • Frank P.G.
        • Marcel Y.L.
        Apolipoprotein A-I: structure-function relationships.
        J. Lipid Res. 2000; 41: 853-872
        • Yokota H.
        • Hashimoto Y.
        • Okubo S.
        • Yumoto M.
        • Mashige F.
        • Kawamura M.
        • et al.
        Apolipoprotein A-I deficiency with accumulated risk for CHD but no symptoms of CHD.
        Atherosclerosis. 2002; 162: 399-407
        • Rifai N.
        • King M.E.
        Immunoturbidimetric assays of apolipoproteins A, AI, AII, and B in serum.
        Clin. Chem. 1986; 32: 957-961
        • Havel R.J.
        • Eder H.A.
        • Bragdon J.H.
        The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum.
        J. Clin. Invest. 1955; 34: 1345-1353
        • Manabe M.
        • Abe T.
        • Nozawa M.
        • Maki A.
        • Hirata M.
        • Itakura H.
        New substrate for determination of serum lecithin:cholesterol acyltransferase.
        J. Lipid Res. 1987; 28: 1206-1215
        • Kataoka S.
        • Paidi M.
        • Howard B.V.
        Simplified isoelectric focusing/immunoblotting determination of apoprotein E phenotype.
        Clin. Chem. 1994; 40: 11-13
        • Huang W.
        • Sasaki J.
        • Matsunaga A.
        • Nanimatsu H.
        • Moriyama K.
        • Han H.
        • et al.
        A novel homozygous missense mutation in the apo A-I gene with apo A-I deficiency.
        Arterioscler. Thromb. Vasc. Biol. 1998; 18: 389-396
        • Blanche P.J.
        • Gong E.L.
        • Forte T.M.
        • Nichols A.V.
        Characterization of human high-density lipoproteins by gradient gel electrophoresis.
        Biochim. Biophys. Acta. 1981; 665: 408-419
        • Takada Y.
        • Sasaki J.
        • Seki M.
        • Ogata S.
        • Teranishi Y.
        • Arakawa K.
        Characterization of a new human apolipoprotein A-I Yame by direct sequencing of polymerase chain reaction-amplified DNA.
        J. Lipid Res. 1991; 32: 1275-1280
        • Shoulders C.C.
        • Kornblihtt A.R.
        • Munro B.S.
        • Baralle F.E.
        Gene structure of human apolipoprotein A1.
        Nucleic Acids Res. 1983; 11: 2827-2837
        • Matsunaga A.
        • Sasaki J.
        • Han H.
        • Huang W.
        • Kugi M.
        • Koga T.
        • et al.
        Compound heterozygosity for an apolipoprotein A1 gene promoter mutation and a structural nonsense mutation with apolipoprotein A1 deficiency.
        Arterioscler. Thromb. Vasc. Biol. 1999; 19: 348-355
        • Araki K.
        • Sasaki J.
        • Matsunaga A.
        • Takada Y.
        • Moriyama K.
        • Hidaka K.
        • et al.
        Characterization of two new human apolipoprotein A-I variants: apolipoprotein A-I Tsushima (Trp-108→Arg) and A-I Hita (Ala-95→Asp).
        Biochim. Biophys. Acta. 1994; 1214: 272-278
        • Matsunaga T.
        • Hiasa Y.
        • Yanagi H.T.M.
        • Hattori N.
        • Yamakawa K.
        • Yamanouchi Y.
        • et al.
        Apolipoprotein A-I deficiency due to a codon 84 nonsense mutation of the apolipoprotein A-I gene.
        Proc. Natl. Acad. Sci. USA. 1991; 88: 2793-2797
        • von Eckardstein A.
        • Assmann G.
        High density lipoproteins and reverse cholesterol transport: lessons from mutations.
        Atherosclerosis. 1998; 137: S7-S11
        • Ng D.S.
        • O’Connor P.W.
        • Mortimer C.B.
        • Leiter L.A.
        • Connelly P.W.
        • Hegele R.A.
        Case report: retinopathy and neuropathy associated with complete apolipoprotein A-I deficiency.
        Am. J. Med. Sci. 1996; 312: 30-33
        • Rader D.J.
        • Ikewaki K.
        Unravelling high density lipoprotein-apolipoprotein metabolism in human mutants and animal models.
        Curr. Opin. Lipidol. 1996; 7: 117-123
        • Roosbeek S.
        • Vanloo B.
        • Duverger N.
        • Caster H.
        • Breyne J.
        • De Beun I.
        • et al.
        Three arginine residues in apolipoprotein A-I are critical for activation of lecithin:cholesterol acyltransferase.
        J. Lipid Res. 2001; 42: 31-40
        • Kuivenhoven J.A.
        • Pritchard H.
        • Hill J.
        • Frohlich J.
        • Assmann G.
        • Kastelein J.
        The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes.
        J. Lipid Res. 1997; 38: 191-205
        • Miccoli R.
        • Bertolotto A.
        • Navalesi R.
        • Odoguardi L.
        • Boni A.
        • Wessling J.
        • et al.
        Compound heterozygosity for a structural apolipoprotein A-I variant, apo A-I(L141R)Pisa, and an apolipoprotein A-I null allele in patients with absence of HDL cholesterol, corneal opacifications, and coronary heart disease.
        Circulation. 1996; 94: 1622-1628
        • Moriyama K.
        • Sasaki J.
        • Takada Y.
        • Matsunaga A.
        • Fukui J.
        • Albers J.J.
        • et al.
        A cysteine-containing truncated apo A-I variant associated with HDL deficiency.
        Arterioscler. Thromb. Vasc. Biol. 1996; 16: 1416-1423